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Abstract 
Background: To study the various FAB and WHO 
subtypes of MDS and prognostic stratification of 
patients at the time of their first presentation. 
Methods: In this cross-sectional study one hundred 
and thirty patients of MDS who were initially 
categorized by FAB criteria were studied. Clinical 
and laboratory data of these patients was re- 
evaluated and reclassified according to the WHO 
classification. Inclusion criteria was patients of  all 
age groups presenting with low haemoglobin , 
neutropenia and/or thrombocytopenia and those 
having transfusion dependent  anaemia. These 
patients also had peripheral blood film showing 
dysplastic changes ,hypo granular neutrophils, 
pseudo-pelger Huet anomalies, dyserythropoietic 
features or absolute monocyte count > 1.6x109/L. 
Patients having a known cause of pancytopenia, 
chronic infection, folate or B12 deficiency or 
concomitant malignancy and those who had received 
chemotherapy or radiotherapy were excluded. 
Diagnosis of MDS was made according to the 
proposals made by FAB as well as by WHO criteria. 
Marrow biopsy was assessed for abnormal 
localization of immature precursors (ALIP), 
lymphoid follicles and reticulin fibrosis. 
Bournemouth prognostic scoring system was applied 
to these patients, score was calculated by marrow 
blast percentage, haemoglobin level, platelet count 
and absolute neutrophil count. 
Results: Amongst 130 patients of MDS, 89 were 
males and 41 females. The median age of patients 
was 48 years (range 9-87 years). In FAB types 
refractory anaemia (RA) was the commonest, while 
according to WHO criteria Refractory Cytopenia 
with Multilineage Dysplasia (RCMD) was 
commonest .Peripheral blood counts revealed a 
varied spectrum of cytopenias ranging from 
anaemia, leucopenia, thrombocytopenia to  
pancytopenia. Eighteen (13.8%) cases were excluded 
while classifying the patients by WHO criteria; these 
included 05 cases of CMML and 13 cases of (RAEB-t) 
having blast cells between 20 and 30%.Majority of 
patients (57%) were found in group B; these were 
followed by 31.5% of patients in group C . 
Conclusion: WHO classification provides more 
homogenous morphological  distribution in the 
subgroups of MDS and better prognostic 
information than FAB classification. 
Key Words: Myelodysplastic syndromes, FAB 
classification ,WHO classification ,Bournemouth 
scoring. 
Introduction 
     Myelodysplastic Syndrome (MDS)  is a large group 
of acquired neoplastic disorders of the bone marrow, 
most commonly in the elderly  and characterized by 
increasing bone marrow failure with quantitative and 
qualitative abnormalities of all three haemopoietic  
cells lines ( red cells, granulocytes and platelets), due 
to a defect in stem cell. A hall mark of the disease  is 
ineffective haemopoiesis so that cytopenias often 
accompany a marrow of normal or increased 
cellularity.  The underlying pathogenetic mechanisms 
include mutations in stem cell, dysregulated 
signalling, haplo- insufficiency, epigenetic changes 
and abnormalities in cytokines , immune system  and 
bone marrow stroma.1 Reprogramming of 
Mesenchymal Stem cells by Haematopoietic cells is an 
initial step followed by events facilitating disease 
progression.2 Peripheral blood cytopenias in 
combination with a hypercellular bone marrow 
exhibiting dysplastic changes are the hall mark of 
MDS. The clinical history of these disorders ranges 
from a chronic to rapid course towards leukaemic 
progression.3 
    The international group of haematologists, the 
French, American, British(FAB) cooperative group 
introduced a classification system in year 1982 for the 
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diagnosis and categorization of MDS. This 
classification was used almost for 20 years .In year 
1999 World Health Organization (WHO)introduced a 
new classification to strengthen the prognostic 
usefulness of the classification system.4 FAB sub 
groups were heterogeneous in terms of morphological 
features and prognosis.5 Some cases of MDS were not 
readily categorized by the FAB criteria e.g. therapy 
related MDS.6Hypoplastic MDS and MDS with bone 
marrow fibrosis were not included in FAB 
classification.7  Prognostic limitations of the FAB 
classification became apparent with variable clinical 
outcome within the FAB subtype.7 The most recent 
classification system of MDS was published in yr 2001 
by the World Health Organization (WHO).8 This 
classification is a modification of FAB classification, 
incorporating clinical features , morphology and 
genetic data .It was the outcome of cooperative efforts 
among international experts in haematopathology and 
clinical Oncologic haematologists. This classification 
provides more homogenous MDS categories.This 
classification system differs from the FAB in the 
following ways: 
1 The proportion of blasts required for diagnosis of 
acute leukaemia  is lowered from 30% to 20%8 
2 The FAB categories of RAEB-t  and CMML no 
longer exist in the new classification.9,10,11 
3 The diagnostic criteria for refractory anaemia with 
or without ringed sideroblasts are considerably 
stricter in WHO classification system.8 
4 The WHO recognizes RCMD and MDS with an 
isolated 5q deletion and secondary MDS as 
distinct categories of MDS.8 
 
Patients and Methods  
    This descriptive and cross-sectional study was 
conducted at department of Haematology, Armed 
Forces Institute of Pathology Rawalpindi, over a 
period of one year (2005-2006). One hundred and 
thirty patients of MDS who were initially categorized 
by FAB criteria were studied. Clinical and laboratory 
data of these patients was re- evaluated and 
reclassified according to the WHO classification. 
Inclusion criteria was all age groups presenting with 
low haemoglobin , neutropenia and/or 
thrombocytopenia and those having transfusion 
dependent  anaemia . These patients also had 
peripheral blood film showing dysplastic changes 
,hypo granular neutrophils, pseudo-pelger Huet 
anomalies, dyserythropoietic features or absolute 
monocyte count > 1.6x109/L. Patients having a known 
cause of pancytopenia, chronic infection, folate or B12 
deficiency,  myelodysplasia due to infection, or 
concomitant malignancy and those who had received 
chemotherapy or radiotherapy were excluded. 
Complete blood counts with differential counts and 
bone marrow aspiration was performed in all these 
patients.  Peripheral blood smear and bone marrow 
aspiration slides were stained with Giemsa stain; Iron 
staining was done by Perl’s stain in all aspirates. 
Cytochemical stains like Myeloperoxidase, Periodic 
Acid Schifff’s(PAS)stain,Neutrophil Alkaline 
Phosphatase (NAP),Sudan black were performed 
whenever required. Bone marrow biopsy was stained 
by Haematoxylin and Eosin stains, Reticulin stain was 
done by Trichrome method. Diagnosis of MDS was 
made according to the proposals made by FAB as well 
as by WHO criteria.8 Marrow biopsy was assessed for 
abnormal localization of immature precursors (ALIP), 
lymphoid follicles and Reticulin fibrosis according to 
RIOS et al proposals.12 Bournemouth prognostic 
scoring system13 was applied to these patients, score 
was calculated by marrow blast percentage, 
haemoglobin level, platelet count and absolute 
neutrophil count. 
Results 
    Amongst 130 patients of MDS, 89 were males and 41 
females. The median age of patients was 48 years 
(range 9-87 years). In FAB types refractory anaemia 
was the commonest, while according to WHO criteria 
Refractory cytopenia with multilineage dysplasia was 
commonest (Table 1)Peripheral blood counts revealed 
a varied spectrum of cytopenias ranging from 
anaemia, leucopenia, thrombocytopenia to  
pancytopenia (Table 2). Eighteen (13.8%) cases were 
excluded while classifying the patients by WHO 
criteria; these included 05 cases of CMML and 13 cases 
of (RAEB-t) having blast cells between 20 and 
30%.Majority of patients (57%) were found in group B; 
these were followed by 31.5% of patients in group C; 
group A was the least frequent, observed in 11.5% of 
patients (Table 3). 
 
Discussion 
    The definition of MDS emerged from observation of 
patients with cytopenias, who failed to respond to 
haematenics or steroids. After a protracted indolent 
course, many developed rapidly fatal acute myeloid 
leukaemia. Non of the terms coined e.g., 
preleukaemia, oligoblastic leukaemia, smouldering 
leukaemia etc, encompassed all the features they 
shared, and the hazy boundary that separated them 
from acute leukaemia was an obstacle to the 
recruitment of patients into clinical trials.    
Journal of Rawalpindi Medical College (JRMC); 2015;19(1):2-6 
 
 4 
Table 1: Myelodysplastic Syndromes –Types 
and age distribution 
Type No(%) Age Range (Mean+ SD) 
FAB types  of MDS (n=130) 
Refractory Anaemia 
(RA) 
 
 57 (43.8%) 11 – 87(52+ 18.74) 
Refractory Anaemia 
with Ringed 
Sideroblasts(RARS) 
 
 06 (4.6%) 30 – 70(49 + 14.8) 
Refractory Anaemia 
with Excess 
Blasts(RAEB) 
 
 49 (37.7%) 9 – 87(33 + 20.9) 
Refractory Anaemia 
with Excess Blasts in 
Transformation 
(RAEB-t) 
 
 13 (10%) 12 – 73(40 + 19.9) 
Chronic Myelo 
Monocytic Leukaemia 
(CMML) 
 
 05 (3.8%) 55 – 75(60 + 7.5) 
WHO Types (n=113) 
Refractory Anaemia 
(RA) 
 
25 (22.3%) 
22 – 80(50 + 17.4) 
Refractory Anaemia 
with Ringed 
Sideroblasts(RARS) 
 
05 (4.5%) 30 – 70(48 + 15.4) 
Refractory Cytopenia 
with Mmultilineage 
Dysplasia( RCMD) 
 
31 (27.7%) 11 – 80(60 + 20.0) 
 
Refractory Cytopenia 
with Multilineage 
Dysplasia with 
Ringed Sideroblasts 
(RCMD-RS) 
 
01 (0.9%) 60(–) 
Refractory Anaemia 
with Excess Blasts-2 
(RAEB-1) 
 
22 (19.6%) 10 – 87(37 + 21.5) 
Refractory Anaemia 
with Excess Blasts-1 
RAEB-2 
 
27 (24.1%) 9 – 75(32 + 20.4) 
Unclassified  
 
01 (0.9%) 35(–) 
Note: (1) 13 cases of RAEB-t and 5 cases of CMML were 
excluded according to the WHO criteria. (2) 5q syndrome 
was not identified in this study 
 
     MDS encompass a range of acquired  clonal 
disorders of haemopoiesis , exhibiting characteristic 
morphological abnormalities of the blood and bone 
marrow cells resulting from maturation abnormalities 
in one or more haemopoietic cell  lines. First and the 
largest study comparing  FAB and WHO classification 
was done by Germing et al on 1600 MDS patients 
previously diagnosed by FAB classification , later on 
such studies comparing these classification systems 
were reported from Austria15, 
Brazil,China,IndiaKorea,Japan.13-20  
 
Table 2: Myelodysplastic Syndrome- 
Haematological parameters 
Type Haemoglobin 
  g/dl 
Mean + SD 
Total 
leucocytes 
count 
 X 10 9/l  
Platelet count 
 X 10 9/l 
FAB Types  
RA 2.6 – 12.7 
7.0 +1.7 
0.6 – 6.1 
2.0 + 1.0 
8 – 290 
93 + 64 
RARS 
2.7 – 6.6 
5.5 + 1.4 
0.4 – 2.6 
1.6 + 0.82 
43 – 205 
86 + 62 
RAEB 
3.6 – 12.2 
7.0 + 1.9 
0.4 – 3.1 
1.4 + 0.6 
7 – 210 
61 + 40 
RAEB-t 
5.5 – 9.6 
7.0 + 1.2 
0.8 – 2.3 
1.6 + 0.3 
7 – 136 
36 + 31 
CMML 
6.9 – 12.1 
9.3 + 2.1 
5.8 – 11.1 
8.0 + 2.5 
10 – 241 
135 + 99 
WHO Types  
RA 
32. – 9.6 
6.8 + 1.3 
0.8 – 6.1 
2.0 + 1.2 
8 – 190 
80.2 + 53.5 
RARS 2.7 – 6.6 
5.2 + 1.5 
0.4 – 2.6 
1.56 + 0.88 
44 – 205 
95.2 + 65.2 
RCMD 5.5 2.1 43 
RCMD-RS – – – 
RAEB-1 3.6 – 12.2 
6.7 + 2.2 
0.4 – 3.1 
1.4 + 0.7 
07 – 120 
58 + 31.4 
RAEB-2 4.5 – 9.6 
7.0 + 1.5 
0.7 – 2.4 
1.5 + 0.6 
08 – 210 
63 + 46 
Unclassified  10.2 
 
1.9 220 
 
Table 3: Scoring system in 130 patients of 
Myelodysplastic syndrome (Bournemouth score) 
Variable Score 
Hb (g/dl) <10 1 
Neutrophils (x109/L) <2.5 1 
Platelets (x 109/L) <100 1 
Bone Marrow blast (%) >5 1 
Prognostic groups (point score) 
Group A        (0-1)                15 cases (11.5%) 
Group B        (2-3)                74 cases (57%) 
Group C        (>3)                41 cases (31.5%) 
 
     A few studies regarding the disease pattern and 
treatment strategies in MDS have been published in 
Pakistan 21, 22, 23In present study according to the FAB 
classification the commonest sub-group was RA 
(43.8%) followed by RAEB (37.7%). RARS (4.6%) and 
CMML (3.8%) were relatively uncommon subgroups.  
According to the WHO system, RCMD comprised 
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almost half the cases that were classified as RA 
according to the FAB criteria; in these cases cytopenias 
and dysmyelopoietic changes were significant, though 
the blast count in marrow was below 05%. There was 
only one case in the unclassified group. RA according  
to FAB and RCMD according to WHO criteria were 
the commonest subgroups in Japan (40%), UK20 
(37.6%), Austria (33%), Korea (36%),India (64%) and 
China (39%).15-17-20 As in our study , RARS has been 
observed as a relatively  uncommon entity in Indians 
(5%), Chinese (3%) and Korea (8%).17-19   However in 
various European studies from , UK (14.9%), Spain 
(16%) and Austria (11%), it was more common.15,20 
CMML was un common   subgroup in India (4%), 
Brazil (3.3%) and Japan  (6.1%) , this finding is 
comparable to our study, however CMML was more 
frequent in UK (22%), Spain(24%) and Austria (23%) 
(Table  4& 5).15,18,20  
     MDS is generally considered as a disorder of 
elderly population in European studies, Median age in 
UK , Spain , and Austria  ranged between 68 and 73 
years.15,20 However in Asian countries including 
India(45 years),China(50 years) and Japan (60) years, 
the Median age is relatively lower, Median age of our 
patients was (48 years) and anaemia was the most 
common cytopenia. 17,18,20 
    Before the introduction of WHO classification 
additional risk based stratification system were 
devised like Bournmouth,Sanz, IPSS for 
prognostication . 13 Due to the marked variation in the 
clinical features and outcome of MDS patients, scoring 
system is a useful tool for therapeutic strategies.13 
Bournemouth scoring system  is presently the most 
convenient system to determine prognosis in our 
setup. Patients were categorized as follows; 11.5% 
cases in low risk group (A), 57% cases in high risk 
group (B), and 31.5% in high risk group (C). It 
revealed that most 0f our patients were in high risk 
group and were investigated at late stage of their 
disease.The aim of prognostic stratification was to help 
the clinicians to decide and plan treatment modalities 
according to disease stage.  WHO classification seems 
to improve management  of MDS patients because 
FAB does not consider potential impact of cytopenias 
and dysmyelopoietic  changes, where as WHO 
classification incorporate most significant variables for 
determination of survival and AML evolution like 
marrow blast percentage , cytopenias ,dysplasia and 
cytogenetics. WHO classification can be adopted in 
routine practice because it provides a useful 
framework for accurately classifying the patients into 
homogenous groups, which is greatly beneficial for 
risk stratification and treatment strategies 
 
Table 4:  Comparison of French American 
British classification of various studies 
Coun
tries 
No 
of 
patie
nts 
Medi
an 
age 
(yrs) 
RA RAR
S 
RAE
B 
RAE
B-t 
CM
ML 
Prese-
nt 
study  
130 48 57 
(44%) 
06   
(5%) 
49 
(37%)  
13 
(10%) 
05 
 (4%) 
India  96 45 61 
(64%) 
05  
(5%) 
21 
(22%) 
05   
(5%) 
04  
(4%) 
Korea  227 57 82 
(36%) 
19  
(8%) 
90 
(40%) 
27 
(12%) 
9   
(4%) 
Aust-
ria  
431 73 142 
(33%) 
47 
(11%) 
92 
(21%) 
51 
(12%) 
99 
(23%) 
Brazil  150 58 90 
(60%) 
18 
(12%) 
34 
(23%) 
03   
(2%) 
05 
(3%) 
 
Table 5:  Comparison of World Health 
Organization classification of various studies 
Countrie
s 
No of 
patient 
Media
-n age 
(years) 
RA RARS RCM
D 
RCM
D RS 
RAEB-
1 
RAEB-
2 
Un-
classifi
ed 
5q del 
Our 
study  
112 48 25 
(22.3
%) 
5   
(4.5%) 
31 
(27.7%
) 
01   
(0.9%) 
22   
(19.6%
) 
31   
(24.1%
) 
01     
(0.9%) 
- 
India  87 45 17 
(20%) 
01 
(1%) 
44 
(50%) 
04  
(5%) 
10  
(12%) 
09  
(10%) 
02     
(2%) 
- 
Korea  176 57 22              
(22%) 
65 
(37%) 
- 51  
(29%) 
37  
(21%) 
1       
(1%) 
- 
Austria  281 73 43 
(15%) 
4  
(1.5%) 
91 
(32%) 
- 50 
(18%) 
42 
(15%) 
50 
(18%) 
1 
(0.7% 
Brazil  142 58 41(29
%) 
18 
(13%) 
25 
(17%) 
- 18 
(13%) 
16 
(11%) 
23 
(16%) 
1 (1%) 
 
Conclusions 
1. In our set up median age of MDS is relatively 
  lower as compared to European  patients of MDS 
2. Majority of MDS patients in our set up are high 
risk group 
3. MDS is likely to become more prevalent with 
increase in aging population  
4. WHO classification provides more homogenous 
distribution in the subgroups of MDS and better 
prognostic information than FAB classification 
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